Sabizabulin trial for COVID-19 treatment stopped early; Emergency Use Authorization to be requested for booster dose in 5 to 11 year-olds; greater diversity called for in clinical trials; myopericarditis risk compared for COVID-19 vaccines vs other vaccines; and survey results of unvaccinated attitudes following FDA approval of a COVID-19 vaccine.